Arbutus Biopharma Corporation
ABUS
$2.98
$0.093.11%
| 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -17.88M | -19.31M | -20.10M | -17.09M | -16.34M |
| Total Depreciation and Amortization | 355.00K | 359.00K | 369.00K | 342.00K | 334.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.08M | 174.00K | 1.33M | 1.20M | 1.04M |
| Change in Net Operating Assets | -2.86M | 1.49M | -3.38M | -4.00M | -12.33M |
| Cash from Operations | -19.30M | -17.29M | -21.78M | -19.56M | -27.30M |
| Capital Expenditure | -95.00K | 0.00 | -32.00K | -859.00K | -117.00K |
| Sale of Property, Plant, and Equipment | -- | 0.00 | 20.00K | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 11.79M | 22.23M | 10.44M | 2.30M | 16.80M |
| Cash from Investing | 11.69M | 22.23M | 10.43M | 1.44M | 16.68M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 24.43M | 3.81M | 1.68M | 4.74M | 20.42M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 24.43M | 3.81M | 1.68M | 4.74M | 20.42M |
| Foreign Exchange rate Adjustments | -13.00K | 14.00K | 8.00K | -1.00K | 4.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 16.82M | 8.75M | -9.67M | -13.38M | 9.80M |
